Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma

Shintarou Kawano, Yanqun Zheng, Kazunari Oobu, Ryota Matsubara, Yuichi Goto, Toru Chikui, Tadamasa Yoshitake, Tamotsu Kiyoshima, Teppei Jinno, Yasuyuki Maruse, Eiji Mitate, ryoji kitamura, Hideaki Tanaka, Takeshi Toyoshima, Tsuyoshi Sugiura, Seiji Nakamura

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

The administration of pre-operative chemotherapy with S-1 and concurrent radiotherapy at a total dose of 30 Gy was clinicopathologically evaluated as a treatment for locally advanced oral squamous cell carcinoma (OSCC) in the present study. The participants comprised 81 patients with OSCC, consisting of 29 patients with stage II disease, 12 patients with stage III disease and 40 patients with stage IV disease. All patients received a total radiation dose of 30 Gy in daily fractions of 2 Gy, 5 times a week, for 3 weeks, and the patients were concurrently administered S-1 at a dose of 80-120 mg, twice daily, over 4 consecutive weeks. Radical surgery was performed in all cases at 2-6 weeks subsequent to the end of pre-operative chemoradiotherapy. The most common adverse event was oropharyngeal mucositis, but this was transient in all patients. No severe hematological or non-hematological toxicities were observed. The clinical and histopathological response rates were 70.4 and 75.3%, respectively. Post-operatively, local failure developed in 6 patients (7.4%) and neck failure developed in 2 patients (2.5%). Distant metastases were found in 7 patients (8.6%). The overall survival rate, disease-specific survival rate and locoregional control rate at 5 years were 87.7, 89.9 and 90.6%, respectively. Locoregional recurrence occurred more frequently in patients that demonstrated a poor histopathological response compared with patients that demonstrated a good response (P<0.01). These results indicate that pre-operative S-1 chemotherapy with radiotherapy at a total dose of 30 Gy is feasible and effective for patients with locally advanced OSCC, and that little or no histopathological response may be a risk factor for locoregional recurrence in this treatment.

元の言語英語
ページ(範囲)3369-3376
ページ数8
ジャーナルOncology Letters
11
発行部数5
DOI
出版物ステータス出版済み - 5 1 2016

Fingerprint

Chemoradiotherapy
Squamous Cell Carcinoma
Therapeutics
Radiotherapy
Survival Rate
Recurrence
Drug Therapy
Mucositis
Neck
Radiation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma. / Kawano, Shintarou; Zheng, Yanqun; Oobu, Kazunari; Matsubara, Ryota; Goto, Yuichi; Chikui, Toru; Yoshitake, Tadamasa; Kiyoshima, Tamotsu; Jinno, Teppei; Maruse, Yasuyuki; Mitate, Eiji; kitamura, ryoji; Tanaka, Hideaki; Toyoshima, Takeshi; Sugiura, Tsuyoshi; Nakamura, Seiji.

:: Oncology Letters, 巻 11, 番号 5, 01.05.2016, p. 3369-3376.

研究成果: ジャーナルへの寄稿記事

@article{6d69e2b664f04051afd1112504f7f5b2,
title = "Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma",
abstract = "The administration of pre-operative chemotherapy with S-1 and concurrent radiotherapy at a total dose of 30 Gy was clinicopathologically evaluated as a treatment for locally advanced oral squamous cell carcinoma (OSCC) in the present study. The participants comprised 81 patients with OSCC, consisting of 29 patients with stage II disease, 12 patients with stage III disease and 40 patients with stage IV disease. All patients received a total radiation dose of 30 Gy in daily fractions of 2 Gy, 5 times a week, for 3 weeks, and the patients were concurrently administered S-1 at a dose of 80-120 mg, twice daily, over 4 consecutive weeks. Radical surgery was performed in all cases at 2-6 weeks subsequent to the end of pre-operative chemoradiotherapy. The most common adverse event was oropharyngeal mucositis, but this was transient in all patients. No severe hematological or non-hematological toxicities were observed. The clinical and histopathological response rates were 70.4 and 75.3{\%}, respectively. Post-operatively, local failure developed in 6 patients (7.4{\%}) and neck failure developed in 2 patients (2.5{\%}). Distant metastases were found in 7 patients (8.6{\%}). The overall survival rate, disease-specific survival rate and locoregional control rate at 5 years were 87.7, 89.9 and 90.6{\%}, respectively. Locoregional recurrence occurred more frequently in patients that demonstrated a poor histopathological response compared with patients that demonstrated a good response (P<0.01). These results indicate that pre-operative S-1 chemotherapy with radiotherapy at a total dose of 30 Gy is feasible and effective for patients with locally advanced OSCC, and that little or no histopathological response may be a risk factor for locoregional recurrence in this treatment.",
author = "Shintarou Kawano and Yanqun Zheng and Kazunari Oobu and Ryota Matsubara and Yuichi Goto and Toru Chikui and Tadamasa Yoshitake and Tamotsu Kiyoshima and Teppei Jinno and Yasuyuki Maruse and Eiji Mitate and ryoji kitamura and Hideaki Tanaka and Takeshi Toyoshima and Tsuyoshi Sugiura and Seiji Nakamura",
year = "2016",
month = "5",
day = "1",
doi = "10.3892/ol.2016.4411",
language = "English",
volume = "11",
pages = "3369--3376",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Clinicopathological evaluation of pre-operative chemoradiotherapy with S-1 as a treatment for locally advanced oral squamous cell carcinoma

AU - Kawano, Shintarou

AU - Zheng, Yanqun

AU - Oobu, Kazunari

AU - Matsubara, Ryota

AU - Goto, Yuichi

AU - Chikui, Toru

AU - Yoshitake, Tadamasa

AU - Kiyoshima, Tamotsu

AU - Jinno, Teppei

AU - Maruse, Yasuyuki

AU - Mitate, Eiji

AU - kitamura, ryoji

AU - Tanaka, Hideaki

AU - Toyoshima, Takeshi

AU - Sugiura, Tsuyoshi

AU - Nakamura, Seiji

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The administration of pre-operative chemotherapy with S-1 and concurrent radiotherapy at a total dose of 30 Gy was clinicopathologically evaluated as a treatment for locally advanced oral squamous cell carcinoma (OSCC) in the present study. The participants comprised 81 patients with OSCC, consisting of 29 patients with stage II disease, 12 patients with stage III disease and 40 patients with stage IV disease. All patients received a total radiation dose of 30 Gy in daily fractions of 2 Gy, 5 times a week, for 3 weeks, and the patients were concurrently administered S-1 at a dose of 80-120 mg, twice daily, over 4 consecutive weeks. Radical surgery was performed in all cases at 2-6 weeks subsequent to the end of pre-operative chemoradiotherapy. The most common adverse event was oropharyngeal mucositis, but this was transient in all patients. No severe hematological or non-hematological toxicities were observed. The clinical and histopathological response rates were 70.4 and 75.3%, respectively. Post-operatively, local failure developed in 6 patients (7.4%) and neck failure developed in 2 patients (2.5%). Distant metastases were found in 7 patients (8.6%). The overall survival rate, disease-specific survival rate and locoregional control rate at 5 years were 87.7, 89.9 and 90.6%, respectively. Locoregional recurrence occurred more frequently in patients that demonstrated a poor histopathological response compared with patients that demonstrated a good response (P<0.01). These results indicate that pre-operative S-1 chemotherapy with radiotherapy at a total dose of 30 Gy is feasible and effective for patients with locally advanced OSCC, and that little or no histopathological response may be a risk factor for locoregional recurrence in this treatment.

AB - The administration of pre-operative chemotherapy with S-1 and concurrent radiotherapy at a total dose of 30 Gy was clinicopathologically evaluated as a treatment for locally advanced oral squamous cell carcinoma (OSCC) in the present study. The participants comprised 81 patients with OSCC, consisting of 29 patients with stage II disease, 12 patients with stage III disease and 40 patients with stage IV disease. All patients received a total radiation dose of 30 Gy in daily fractions of 2 Gy, 5 times a week, for 3 weeks, and the patients were concurrently administered S-1 at a dose of 80-120 mg, twice daily, over 4 consecutive weeks. Radical surgery was performed in all cases at 2-6 weeks subsequent to the end of pre-operative chemoradiotherapy. The most common adverse event was oropharyngeal mucositis, but this was transient in all patients. No severe hematological or non-hematological toxicities were observed. The clinical and histopathological response rates were 70.4 and 75.3%, respectively. Post-operatively, local failure developed in 6 patients (7.4%) and neck failure developed in 2 patients (2.5%). Distant metastases were found in 7 patients (8.6%). The overall survival rate, disease-specific survival rate and locoregional control rate at 5 years were 87.7, 89.9 and 90.6%, respectively. Locoregional recurrence occurred more frequently in patients that demonstrated a poor histopathological response compared with patients that demonstrated a good response (P<0.01). These results indicate that pre-operative S-1 chemotherapy with radiotherapy at a total dose of 30 Gy is feasible and effective for patients with locally advanced OSCC, and that little or no histopathological response may be a risk factor for locoregional recurrence in this treatment.

UR - http://www.scopus.com/inward/record.url?scp=84976904191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976904191&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.4411

DO - 10.3892/ol.2016.4411

M3 - Article

VL - 11

SP - 3369

EP - 3376

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 5

ER -